Pharmaceuticals News and Research

RSS

Kidney transplantation saves life

For more than 20 years Delores Evans battled diabetes, high blood pressure and, finally, kidney failure. By 2008 she needed a new kidney to stay alive, but she never could have imagined the circumstances that brought it about.

29 Dec 2009

Successful RNA interference to turn off multiple genes raises hope for new liver disease treatments

Researchers at MIT and Alnylam Pharmaceuticals report this week that they have successfully used RNA interference to turn off multiple genes in the livers of mice, an advance that could lead to new treatments for diseases of the liver and other organs.

29 Dec 2009

Tego Biosciences sells intellectual property portfolio to Luna Innovations

Arrowhead Research Corporation today announced that its wholly owned subsidiary, Tego Biosciences, has completed a definitive asset purchase agreement for the sale of its non-cash intellectual property (IP) to Luna Innovations, Inc., a developer and manufacturer of new-generation products that include pharmaceutical nanomedicines

29 Dec 2009

Radient Pharmaceuticals receives NYSE Amex non-compliance notice

Radient Pharmaceuticals Corporation today announced it has received notice from the NYSE Amex that the Company is not in compliance with the continued listing standard in Section 1003(a)(iv) of the Exchange's Company Guide. The Company has until January 22, 2010 to submit a plan to regain compliance by June 23, 2010.

29 Dec 2009

SVA submits the first clinical trial application for HFMD vaccine in China

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced today that it has filed the application with China's State Food and Drug Administration (SFDA) to commence a human clinical trial for its vaccine against human enterovirus 71 (EV 71), which causes hand, foot, and mouth disease (HFMD). This is the first clinical trial application for HFMD vaccine submitted in China.

28 Dec 2009

Aeolus Pharmaceuticals reports financial results for three months and twelve months ended September 30, 2009

Aeolus Pharmaceuticals, Inc. announced today financial results for the three months and twelve months ended September 30, 2009. The Company reported a net loss of $746,000, or $0.02 per share, for the three months ended September 30, 2009 compared to a loss of $1,055,000, or $0.03 per share, for the three months ended September 30, 2008.

28 Dec 2009

PhRMA applauds Senate for passing health care reform

"We applaud the Senate for taking an important and historic step toward expanding high-quality, affordable health care coverage and services to tens of millions of Americans, many of whom are struggling today financially. While considerable work remains to be done in reconciling differences between the Senate and House bills, we remain convinced that comprehensive health care reform, if done in a smart way, will benefit patients, our economy and the future of our nation.

27 Dec 2009

SemBioSys Genetics' Apo AI(Milano) program progress update

SemBioSys Genetics Inc. provided an update today on its progress on plant-produced Apo AI(Milano) in light of the Apo AI(Milano) license agreement between Pfizer Inc. and The Medicines Company, of Parsippany, New Jersey.

24 Dec 2009

EGCg in green tea inhibits flu infection

Joint research conducted by the Central Research Institute of ITO EN, Ltd. and Professor Takashi Suzuki of the School of Pharmaceutical Sciences, University of Shizuoka, showed that epigallocatechin gallate (EGCg), a kind of catechin contained in green tea, had an inhibitory effect against three types of influenza viruses, including the swine-origin H1N1 virus that caused pandemic flu in 2009, and that its effect did not depend on the type of virus. These findings once again suggest that green tea is effective in preventing flu.

24 Dec 2009

Salix Pharmaceuticals sued over alleged kidney damage due to OsmoPrep

Suits were commenced Dec. 23, 2009 in North Carolina for four users who allege kidney damage due to the use of OsmoPrep, a prescription drug used to cleanse the intestines in preparation for a colonoscopy. (Holshouser et al v. Salix Pharmaceuticals, Ltd. and Salix Pharmaceuticals. Inc.)

24 Dec 2009

Teva-KOWA Pharma signs definitive agreement to acquire major shares in Taisho Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. announced today that Teva-KOWA Pharma Co., Ltd., the Company's joint venture in Japan with KOWA Company, Ltd., has signed a definitive agreement to acquire a majority of the outstanding shares of Taisho Pharmaceutical Industries, Ltd.

24 Dec 2009

Eli Lilly and Kowa Pharmaceuticals America to co-promote LIVALO in the U.S

Eli Lilly and Company (NYSE: LLY), Kowa Company, Limited, and Kowa's U.S. subsidiary, Kowa Pharmaceuticals America, Inc., today announced that Lilly and Kowa Pharmaceuticals America have entered into a co-promotion agreement in the United States to commercialize LIVALO® (pitavastatin). Lilly and Kowa have also entered into a licensing agreement in Latin America. LIVALO is a statin approved by the U.S. Food and Drug Administration (FDA) in August 2009 for the treatment of primary hyperlipidemia and mixed dyslipidemia.

24 Dec 2009

Oxford Outcomes becomes a member of SAFE-BioPharma Association

Oxford Outcomes, an international health outcomes consultancy, has become a member of SAFE-BioPharma Association, the non-profit association that created and manages the global SAFE-BioPharma® digital identity and signature standard for the pharmaceutical and healthcare industries.

24 Dec 2009

Study reveals genomic switches separate autoimmune disorders in different clusters

Genomic switches can predispose an individual to one set of autoimmune disorders but protect the same person against another set of them, scientists at Stanford University School of Medicine have found.

24 Dec 2009

Drug companies winners of the American prescription drug debate

On Dec. 15, the Obama Administration rejected a plan to allow the wholesale reimportation of cheaper prescriptions drugs from abroad, despite projected intentions to take on the drug industry and secure cheaper prescription for Americans.

24 Dec 2009

Raptor Pharmaceutical completes $7.5 million registered direct offering

Raptor Pharmaceutical Corp. ("Raptor" or the "Company"), today announced that on December 22, 2009, it completed its registered direct offering with institutional investors, raising an aggregate amount of approximately $7.5 million of gross proceeds (before placement agent fees and offering expenses) through the sale of 3,747,558 units.

24 Dec 2009

Orexigen Therapeutics' Compensation Committee approves inducement grants

Orexigen(R) Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, today announced that on December 23, 2009 the Compensation Committee of the Company's Board of Directors approved the grant of inducement stock options to purchase a total of 64,000 shares of common stock to two new employees.

24 Dec 2009

PDI awarded contract sales engagement with Top 5 pharmaceutical company

PDI, Inc., a leading provider of sales and marketing support to U.S. health care companies, has been awarded a significant contract sales engagement with a Top 5 pharmaceutical company. This program is expected to generate approximately $6 million in revenue for PDI during the first quarter of 2010 and may extend through the remainder of 2010.

24 Dec 2009

AstraZeneca signs definitive agreement to acquire Novexel

Novexel, a speciality pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of microbial drug resistance, announces today that its shareholders have signed a definitive agreement whereby Novexel shall be acquired by AstraZeneca for a total cash consideration of up to $505 million, including contingent payments and the net cash position of the company at closing.

24 Dec 2009

Planet Green to be acquired by IMAGIN Molecular

IMAGIN Molecular Corporation (OTCBB: IMGM) has agreed in a letter of intent to issue 49% of the post capitalization of IMGM in exchange for 84,000,000 Positron Corporation common shares plus 100% of the equity of the Planet Green Bottle, all IMGM shares to be distributed to shareholders or affiliates of Planet Green.

24 Dec 2009